Paul Poutouves, DPT in Cheshire, CT - Physical Therapist

Paul Poutouves, DPT is a Physical Therapist physician based in Cheshire, Connecticut. Paul Poutouves is licensed to practice in Connecticut (license number 8498) and his current practice location is 609 W Johnson Ave Ste 21, Cheshire, Connecticut. He can be reached at his office (for appointments etc.) via phone at (516) 351-6224.

NPI number for Paul Poutouves is 1710125026 and his current mailing address is 149 Jubilee Dr, Plantsville, Connecticut. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1710125026.

Contact Information

	Paul Poutouves, DPT
	609 W Johnson Ave Ste 21, Cheshire, CT 06410-4505
	(516) 351-6224
	Not Available

Physician's Profile

Full Name	Paul Poutouves
Gender	Male
Speciality	Physical Therapist
Location	609 W Johnson Ave Ste 21, Cheshire, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1710125026
Provider Enumeration Date: 01/23/2009
Last Update Date: 12/20/2023

Medical Identifiers

Medical identifiers for Paul Poutouves such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1710125026	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2081S0010X	Physical Medicine & Rehabilitation - Sports Medicine	008498 (Connecticut)	Secondary
225100000X	Physical Therapist	8498 (Connecticut)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Paul Poutouves is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Paul Poutouves, DPT 149 Jubilee Dr, Plantsville, CT 06479-1029 Ph: (516) 351-6224	Paul Poutouves, DPT 609 W Johnson Ave Ste 21, Cheshire, CT 06410-4505 Ph: (516) 351-6224

News Archive

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

Researchers uncover how GWAS-implicated gene affects HDL-cholesterol levels

Researchers have uncovered how genes identified from genome-wide association studies (GWAS) affect high-density lipoprotein cholesterol (HDL-C), a biomarker of cardiovascular disease, after comparing several animal models with human patient data.

Leeches add interesting new angle for evolutionary biologists to consider when explaining how parental care has evolved

When it comes to parenting, leeches are quite accomplished. Although some leeches abandon their young at birth, a Monash University study of the Australian leech species, Helobdella papillornata, has found that it broods its eggs and young on its body for several weeks and captures food for its offspring.

Researchers find molecule ephrin-B3 inhibits regrowth of spinal nerve cells

A molecule that helps the body's motor nerve cells grow along proper paths during embryonic development also plays a major role in inhibiting spinal-cord neurons from regenerating after injury, researchers at UT Southwestern Medical Center have found.

Paul Poutouves, DPT - Physical Therapist in Cheshire, CT